Fundraising Fox

Renova Therapeutics

Carlsbad, US · 1 known investors

Renova Therapeutics develops investigational gene therapies intended as single-dose, long-lasting treatments for common chronic diseases, with an initial focus on congestive heart failure and type 2 diabetes. The company builds a platform of therapeutics and delivery systems based on proprietary insights into disease mechanisms.

BiotechHealthtech

Founders & leadership

KH
Kirk HammondFounder
SSShawn Swaney
Shawn SwaneyinChief Financial Officer and Chief Operating Officer

Board

RC
Roy CosanBoard director
PL
Pierre LecocqBoard director
VM
Vijay MahantBoard director
MT
Michael TorresBoard director
WD
William DavidsonBoard director
MX
Morgan XuBoard director

Investors · 1

BioBritLa Jolla

Reported raises · per SEC filings

Form D private placements

$166.5K disclosed across 1 round · 2024

▶$166.5KraisedSep 2024 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Roy CosanDirector
  • Pierre LecocqDirector
  • Vijay MahantDirector
  • Michael TorresDirector
  • Kirk HammondDirector
  • William DavidsonDirector
  • Morgan XuDirector
  • Shawn SwaneyExecutive Officer
Offering amount
$500K
Amount sold
$166.5K
First sale
Jul 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Renovo Rx24 shared keywordsRenovoRx develops targeted oncology therapies and commercializes the RenovoCath, an FDA-cleared drug-delivery device for intra-arterial chemotherapy administration in cancer treatment. The company is conducting Phase III clinical trials of its proprietary TAMP therapy platform for treating locally advanced pancreatic cancer with improved safety and efficacy compared to systemic chemotherapy.
Rennova Health10 shared keywordsRennova Health is a vertically integrated healthcare company providing diagnostic services and supportive software solutions to healthcare providers. The company delivers integrated technology and diagnostics to improve patient experience and clinical outcomes.

Companies competing with Renova Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase IISTTR2022$1.6M
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2019$241.7K
National Institutes of Health (NIH)National Institutes of HealthPhase IISTTR2016$1.6M
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2014$240.8K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Renova Therapeutics do?
Renova Therapeutics develops investigational gene therapies intended as single-dose, long-lasting treatments for common chronic diseases, with an initial focus on congestive heart failure and type 2 diabetes. The company builds a platform of therapeutics and delivery systems based on proprietary insights into disease mechanisms.
Who founded Renova Therapeutics?
Renova Therapeutics was founded by Kirk Hammond.
Who are Renova Therapeutics's investors?
Renova Therapeutics's investors include BioBrit.
How much funding has Renova Therapeutics raised?
Renova Therapeutics has disclosed $166.5K raised across 1 round.
Where is Renova Therapeutics headquartered?
Renova Therapeutics is headquartered in Carlsbad, US.